Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
A. Nikolakopoulou (Athens, Greece), K. Tzimopoulos (Athens, Greece), E. Tsaroucha (Athens, Greece), K. Kavvada (Athens, Greece), A. Rapti (Athens, Greece). Effectiveness of oral metronomic Vinorelbine versus Docetaxel as second-line treatment in Non-Small Cell Lung Cancer patients in real life. 1697

Member's Comments

No comment yet.

Related content which might interest you: Combination of oral and parenteral vinorelbine with cisplatin or carboplatin in adjuvant chemotherapy of nonsmall cell lung cancer - SWITCH study Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 Single agent gemcitabine or docetaxel in the second-line therapy for patients with non-small cell lung cancer previously treated with platin-based chemotherapy Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 Maintenance therapy with pemetrexed in non-small-cell lung cancer: Impact on survival Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 Consolidation maintenance oral vinorelbine following concurrent chemoradiation of intravenous vinorelbine and cisplatin in patients with unresectable stage III non-small cell lung cancer Source: International Congress 2015 – Advances in the therapy of lung cancer Year: 2015 Survival in 138 patients with non small cell lung cancer (NSCLC) treated with platinum together with gemcitabine or vinorelbine by a multidisciplinary team. Comparison with the Big Lung Trial Source: Eur Respir J 2006; 28: Suppl. 50, 781s Year: 2006 Clinical outcome of S-1 monotherapy in patients with advanced non-small cell lung cancer after treatment of pemetrexed Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 Swedish Lung Cancer Radiation Study Group: The value of induction chemotherapy for radiotherapy response in patients with non-small cell lung cancer Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010 Chemotherapy Source: Eur Respir Monogr 2015; 68: 186-201 Year: 2015 Non-small cell lung cancer treatment: chemotherapy combination gemcitabine – cisplatin – paclitaxel Source: Eur Respir J 2004; 24: Suppl. 48, 302s Year: 2004 A phase II trial of lipoplatin and gemcitabine in patients with NSCLC previously treated with platinum-based chemotherapy Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016 TTF 1- expression and pemetrexed based chemotherapy. A retrospective analysis Source: International Congress 2015 – Diagnosis and therapy of lung cancer Year: 2015 Late Breaking Abstract - Randomized phase III study of erlotinib compared to intercalated erlotinib with cisplatin and pemetrexed as first-line therapy for advanced EGFR mutated non-small cell lung cancer, the NVALT 17 study. Source: Virtual Congress 2021 – New clinical and biological developments in lung cancer Year: 2021 Lung toxicity in a patient treated with sunitinib Source: Eur Respir J 2012; 40: 1300-1303 Year: 2012 Metronomic chemotherapy in human lung cancer: Mathematical modeling for an optimal schedule Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 Safety and efficacy of erlotinib in patients with squamous cell lung cancer Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Efficacy and safety of full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer (NSCLC) patients: Results of a prospective study in nonrandomized population of 259 patients Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 Intratumoral Hyperthermic Chemotherapy Injection in Peripheral Non-Small Cell Lung Cancer; a Pilot Study. Source: Virtual Congress 2020 – Novelties in interventional pulmonology: expanding horizons Year: 2020 Maintenance treatment with erlotinib after induction chemotherapy for advanced NSCLC Source: Annual Congress 2011 - Recent therapeutic advances with tyrosine-kinase inhibitors in nonsmall-cell lung cancer Year: 2011 Gefitinib in front line treatment of patients with NSCLC in the Czech Republic: Analysis of 113 patients Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Anticancer chemotherapy combined with anti-tuberculosis treatment: A systematic review Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013